EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Dong, Rui-Fang; Zhu, Miao-Lin; Liu, Ming-Ming; Xu, Yi-Ting; Yuan, Liu-Liu; Bian, Jing; Xia, Yuan-Zheng; Kong, Ling-Yi

Dong, Rui-Fang; Zhu, Miao-Lin; Liu, Ming-Ming; Xu, Yi-Ting; Yuan, Liu-Liu; Bian, Jing; Xia, Yuan-Zheng; Kong, Ling-Yi.

Dong RF; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Zhu ML; Department of Pathology, Jiangsu Cancer Hospital, 210009 Nanjing, China.
Liu MM; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Xu YT; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Yuan LL; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Bian J; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Xia YZ; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China; Key laboratory of High-Incidence-Tumour Prevention & Treatment (Guangxi M
Kong LY; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China. Electronic address: cpu_lykong@126.com.

Pharmacol Res ; 167: 105583, 2021 05.

Article en En | MEDLINE | ID: mdl-33775864

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas/genética; Resistencia a Antineoplásicos; Neoplasias Pulmonares/genética; Mutación; Inhibidores de Proteínas Quinasas/farmacología; Animales; Antineoplásicos/farmacología; Antineoplásicos/uso terapéutico; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Receptores ErbB/antagonistas & inhibidores; Receptores ErbB/genética; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Mutación/efectos de los fármacos; Inhibidores de Proteínas Quinasas/uso terapéutico

Palabras clave

Alflutinib (PubChem CID: 118861389); Almonertinib (PubChem CID: 121280087); EAI045 (PubChem CID: 121231412); EGFR mutations; EGFR-TKI resistance; Future development; JBJ-04-125-02 (PubChem CID: 124173751); JND3229 (PubChem CID: 137628688); NSCLC; Osimertinib (PubChem CID: 71496458); Overcoming drug resistance; Poziotinib (PubChem CID: 25127713); TAK-788 (PubChem CID: 118607832); TAS6417 (PubChem CID: 117918742); TQB3804 (PubChem CID: 138911391)

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Neoplasias Pulmonares / Mutación Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google